Document is current
Any future updates will be listed below
-
Authors
van der Aart, T. J. https://orcid.org/0000-0002-1518-8603
Molema, G.
Jongman, R. M.
Bouma, H. R.
Koeze, J.
Moser, J.
van Londen, M.
Hackl, M.
Diendorfer, A. B.
ter Maaten, J. C.
van Meurs, M.
Luxen, M.
-
Funding
Funding for this research was provided by:
Ministerie van Economische Zaken en Klimaat
- License Information
-
More Information
Article History
Received: 6 June 2025
Accepted: 13 August 2025
First Online: 2 September 2025
Declarations
:
: This study is embedded in the Acutelines data-biobank (), registered in Clinicaltrials.gov (NCT04615065, November 3rd 2020) [, ], The Biobank Intensive Care Groningen (BICG) and HEALICS registered in Clinicaltrials.gov (NCT04502511, August 6th 2020). These cohort studies are approved by the medical ethics committee of the University Medical Centre Groningen (UMCG), a tertiary care teaching hospital in the Northern Netherlands. All procedures were conducted in accordance with the Helsinki Declaration. Data are pseudonymized to ensure confidentiality and privacy in accordance with European privacy legislation. Informed consent was obtained from all subjects and/or their legal guardian(s).
: Not applicable.
: M. Hackl is co-founder and CEO/CSO of TAmiRNA, which provides small RNA-sequencing and RNA-sequencing analysis services. A. Diendorfer is employed by TAmiRNA. G. Molema is co-founder and CSO/CTO of Vivomicx, which provides laser microdissection analysis services. Vivomicx and TAmiRNA financially contributed to the PPP-allowance. The remaining authors declare no conflicts of interest.
